SCHEMBL21590633

SCHEMBL21590633

CC(C)(O)CCC1(O)CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 12/20 0.49
OPRD1 P41143 11/20 0.49
OPRK1 P41145 11/20 0.49
OPRL1 P41146 11/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GPR55 Q9Y2T6 1/20 0.49
CYP3A4 P08684 4/20 0.44
CYP2D6 P10635 4/20 0.44
CYP2C9 P11712 2/20 0.44
USP2 O75604 1/20 0.44
CYP1A2 P05177 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HIF1A Q16665 1/20 0.40
CYP2C19 P33261 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
ADRA2A P08913 1/20 0.39
ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7691375 0.81 OPRL1 (0.60) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL1489316 0.80 OPRM1 (0.50) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL21639941 0.79 OPRL1 (0.74) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL69083 0.78 OPRM1 (0.56) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL17711323 0.76 OPRM1 (0.59) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL13317173 0.74 OPRM1 (0.51) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL2142315 0.74 OPRM1 (0.51) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL1742229 0.73 OPRM1 (0.71) OPRM1OPRD1OPRK1OPRL1NPSR1
SCHEMBL3834657 0.72 OPRM1 (0.45) OPRM1OPRD1OPRK1OPRL1CYP3A4
SCHEMBL71724 0.72 NPSR1 (0.57) OPRM1OPRD1OPRK1OPRL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840528-B2 Isoxazolyl ether derivatives as GABAA α5 PAM HOFFMANN-LA ROCHE INC. (US) 2023-12-12 US disclosed
EP-3807269-A1 NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM F. Hoffmann-La Roche AG (CH) 2021-04-21 EP disclosed
US-20210094945-A1 NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM HOFFMANN-LA ROCHE INC. (US) 2021-04-01 US disclosed
CN-112424196-A Novel isoxazolyl ether derivatives as GABAA alpha 5 PAM 豪夫迈·罗氏有限公司 2021-02-26 CN disclosed
WO-2019238633-A1 NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM F. HOFFMANN-LA ROCHE AG (CH) 2019-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840528-B2 Isoxazolyl ether derivatives as GABAA α5 PAM GABRA5, GABRA2, GABRB2 OPRM1 157/4885OPRD1 154/4885OPRK1 155/4885
US-20210094945-A1 NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM GABRA5, GABRB2, GABRB1 OPRM1 167/4885OPRD1 117/4885OPRK1 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.